Day: September 13, 2021

– Step-down therapy with MAT2203 achieved effective clearance of fungal organisms; Mean Early Fungicidal Activity (EFA) was 0.38, exceeding the prespecified primary endpoint threshold target of >0.20 – – Overall survival was >95% in 40 patients receiving MAT2203 in Cohort 2 – – All 39 patients completing induction with MAT2203 achieved sterility, with no evidence of breakthrough or recurrent infections during the first 10 weeks of antifungal treatment – – Patients received MAT2203 for up to 6 weeks without kidney toxicity or electrolyte abnormalities attributable to MAT2203 – – DSMB unanimously recommends progression to Cohort 3; Enrollment has commenced – – Preparing to engage with FDA to review EnACT data as supportive of potential early approval of MAT2203 as step-down therapy – – Management to host conference call today, Monday, September...

ROBIT PLC          PRESS RELEASE          13 SEPTEMBER 2021 AT 1.00 P.M.            ROBIT PLC: BUILDING BLOCKS IN PLACE TO REACH THE STRATEGIC TARGETSGrowth company, Robit Group, invites investors, analysts, and financial media to the company’s Capital Markets Day on Thursday 23 September 2021 from 10.00 a.m. until approx. 12.30 p.m. UTC+3. The event will be organized as a hybrid event both online and onsite. The live event venue will be Wanha Satama (F-hall), Kanavakatu 5, FI00160 Helsinki. Speakers and program Strategy for sustainable growth, Tommi Lehtonen, Group CEO ESG in practice, Arto Halonen, Group CFO Partner for mining, George Apostolopoulos, VP Global Sales Geotechnical business – solutions for urbanization, Ville Pohja, VP Geotechnical Towards best-in-class service level, Arto Halonen, Group CFO Plan in numbers, Arto Halonen,...

Relay Therapeutics to host a conference call on October 8th at 12:30 pm E.T. CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced that initial clinical data for RLY-4008 and preclinical data for RLY-2608 have been selected for a plenary oral and poster presentation, respectively, at the upcoming virtual AACR-NCI-EORTC Molecular Targets Conference, being held October 7-10, 2021. RLY-4008 is a potent, selective and oral small molecule inhibitor of FGFR2 that entered a first-in-human clinical trial in September 2020. RLY-2608 is the first allosteric, pan-mutant (H1047X, E542X and E545X), and isoform-selective PI3Kα inhibitor...

Advances distribution into the Canadian medical cannabis marketSimply Bare™ Organic hash and Wildflower Cool and Relief Sticks included in opening orderVANCOUVER, British Columbia, Sept. 13, 2021 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), a licensed producer focused on cultivating and selling organic certified and premium cannabis, is pleased to announce that it signed a Cannabis Products Supplier Agreement with Medical Cannabis by Shoppers Drug Mart Inc. (“Shoppers”). The supply agreement with Shoppers includes Simply Bare™ Organic hash, as well as both Wildflower CBD Relief Sticks and Wildflower CBD Cool Sticks in both 30g and 73g product formats. These products will be made available on the Medical Cannabis by Shoppers™ platform. “Rubicon Organics has made...

PALISADE Phase 3 Program focused on PH94B’s potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) — VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the initiation of PALISADE-2, the second U.S. Phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of PH94B for the acute treatment of anxiety in adults with social anxiety disorder (“SAD”). PH94B is designed to be an odorless, rapid-onset pherine nasal spray with a unique potential mechanism of action for the acute treatment of anxiety...

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that members of the senior leadership team will participate in two upcoming virtual investment conferences in September 2021. H. C. Wainwright 23rd Annual Global Investment Conference (September 13-15, 2021)Format: Company Presentation Presentation: Available On-Demand beginning September 13, 2021 at 7:00 a.m. Eastern Time (ET)Cantor Fitzgerald Global Healthcare Conference 2021 (September 27-30, 2021)Format: Company presentation Presentation Date/Time: September 28, 2021 at 2:40 p.m. ETBoth presentations will be webcast live and archived for 90 days on the Amarin Corp. website in the Events section of the Investor Relations site. About AmarinAmarin is an innovative pharmaceutical company leading...

TORONTO, Sept. 13, 2021 (GLOBE NEWSWIRE) — FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) (“FuelPositive” or the “Company”) is issuing the following update to share the status of the company and its various initiatives. FuelPositive is a Canadian growth-stage technology company committed to providing commercially viable and sustainable, “cradle to cradle”, clean energy solutions to combat climate change. Its lead technology is a system for producing carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications. “Having received extensive interest from investors and potential partners since our last corporate update on July 15, we felt it would be helpful to share how we are progressing, particularly regarding the building of our Phase 2 Hydrogen-Ammonia Synthesizer commercial prototype systems,”...

VANCOUVER, British Columbia, Sept. 13, 2021 (GLOBE NEWSWIRE) — Fobi AI Inc. (TSX.V: FOBI) (OTCQB: FOBIF) (the “Company” or “Fobi”), a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, is pleased to announce that it has developed and released a new universal app-less proof of vaccination validation solution, CheckVax™ Validator, to support Smart Health Cards (SHCs) https://smarthealth.cards/ which to date have been adopted to validate vaccination credentials in California, New York and Louisiana, British Columbia and Quebec. Fobi believes that CheckVax™ Validator is the only app-less solution available on the market today that will validate all proof of vaccination credentials. Fobi CEO Rob Anson states: “As we are fielding inquiries...

VANCOUVER, Washington, Sept. 13, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer and Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development of CytoDyn will provide a comprehensive business update at the upcoming Emerging Growth Conference. CytoDyn will present for 20 minutes, and 40 minutes will be dedicated to live questions and answers.Date: Wednesday, September 15, 2021Time: 3:30 pm ET – 4:30 pm ETAccess: https://goto.webcasts.com/starthere.jsp?ei=1487778&tp_key=ec487e0e97&sti=cydyInterested participants...

Figure 1Location map of the Lagoa Salgada Property (IPB)Graph 1Sensitivities of pre-tax and post-tax NPV and IRR to metal prices per ounce(All amounts referred to are in US$ currency)Low capital intensive project with pre production capital cost of $132 million and a post tax payback of 1.5 years Post tax NPV8% of $246 Million and Post tax IRR of 55%; Average EBITDA of approximately US$117 million and Post Tax Free Cash Flow of approximately US$82 million per annum for the first 5 years; Initial Operating Mine Life of 14 years with average throughput of 2.0 million tpa from the North and South Zones of Venda Nova Area at Lagoa Salgada World Class Infrastructure in place including existing major highway, water dam, high voltage power line and rail line to nearest ports supporting rapid development Ascendant...